title: VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.
abstract: With the recent advances in genomic medicine and the development of targeted antiangiogenic therapy for cancer patients, there has been an increased interest in the role of predictive and prognostic markers for antiangiogenic therapy. Here, we provide a summary of the angiogenesis pathway, the role of predictive and prognostic markers in cancer and a summary of the current literature and studies on predictive and prognostic markers for antiangiogenic therapy. Our aim is to summarize those studies that are currently in the literature with an emphasis on the future directions of the field from 2013 and beyond. We conclude by providing our perspective on the future directions of this growing field, as well as possible challenges and pitfalls along the way.
authors.affiliation: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Hospital/University of Toronto, Toronto, ON, Canada.
authors.forename: Lawson
authors.initials: L
authors.lastname: Eng
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Liu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A